SCHEMBL2519926

SCHEMBL2519926

Cc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)CO4)n2)cnc1N1CCOC(C)(C)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 16/20 0.54
ADORA3 P0DMS8 2/20 0.44
TYRO3 Q06418 2/20 0.44
JAK1 P23458 2/20 0.44
JAK3 P52333 2/20 0.44
EGFR P00533 2/20 0.44
PLK4 O00444 2/20 0.44
AURKA O14965 2/20 0.44
STK16 O75716 2/20 0.44
RET P07949 2/20 0.44
FLT3 P36888 2/20 0.44
MAPK8 P45983 2/20 0.44
MAPK9 P45984 2/20 0.44
MST1R Q04912 2/20 0.44
PTK2 Q05397 2/20 0.44
TNK1 Q13470 2/20 0.44
IKBKE Q14164 2/20 0.44
MAP3K11 Q16584 2/20 0.44
ADCK1 Q86TW2 2/20 0.44
PIP4K2C Q8TBX8 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2523157 0.95 SYK (0.56) SYKADORA3TYRO3JAK1JAK3
SCHEMBL2517933 0.90 SYK (0.57) SYKADORA3TYRO3JAK1JAK3
SCHEMBL2521194 0.89 SYK (0.58) SYKADORA3TYRO3JAK1JAK3
SCHEMBL2523175 0.88 SYK (0.54) SYKADORA3TYRO3JAK1JAK3
SCHEMBL2517891 0.88 SYK (0.54) SYKADORA3TYRO3JAK1JAK3
SCHEMBL2527690 0.84 SYK (0.58) SYKADORA3TYRO3JAK1JAK3
SCHEMBL2525501 0.83 SYK (0.60) SYKADORA3TYRO3JAK1JAK3
SCHEMBL12212907 0.81 SYK (0.57) SYKADORA3TYRO3JAK1JAK3
SCHEMBL2525986 0.79 SYK (0.61) SYKADORA3TYRO3JAK1JAK3
SCHEMBL2523080 0.79 SYK (0.63) SYKADORA3TYRO3JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2558474-B1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-11-25 EP claimed
US-8618095-B2 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses RIGEL PHARMACEUTICALS, INC. (US) 2013-12-31 US claimed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 US claimed
EP-2558474-B1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS INC (US) 2015-11-25 EP disclosed
US-8618095-B2 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses RIGEL PHARMACEUTICALS, INC. (US) 2013-12-31 US disclosed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES TYMP, DPYD, TYMS SYK 1871/4885ADORA3 216/4885TYRO3 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.